ZLDPF (Zealand Pharma AS) EBIT per Share : $-2.28 (TTM As of Sep. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Zealand Pharma AS EBIT per Share?

Zealand Pharma AS's EBIT per Share for the three months ended in Sep. 2024 was $-0.55. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $-2.28.

During the past 3 years, the average EBIT per Share Growth Rate was 14.50% per year. During the past 5 years, the average EBIT per Share Growth Rate was 9.70% per year. During the past 10 years, the average EBIT per Share Growth Rate was -15.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Zealand Pharma AS's EBIT per Share or its related term are showing as below:

ZLDPF' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -82.5 Med: -15.15 Max: 15.8
Current: 14.5

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Zealand Pharma AS was 15.80% per year. The lowest was -82.50% per year. And the median was -15.15% per year.

ZLDPF's 3-Year EBIT Growth Rate is ranked better than
66.8% of 1250 companies
in the Biotechnology industry
Industry Median: 2.8 vs ZLDPF: 14.50

Zealand Pharma AS's EBIT for the three months ended in Sep. 2024 was $-38.55 Mil.

Zealand Pharma AS EBIT per Share Historical Data

The historical data trend for Zealand Pharma AS's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma AS EBIT per Share Chart

Zealand Pharma AS Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-2.52

-2.86

-2.68

-2.82

-1.77

Zealand Pharma AS Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT per Share	Get a 7-Day Free Trial															0.18	-0.66	-0.53	-0.54	-0.55

Zealand Pharma AS EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Zealand Pharma AS's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-100.073	/	56.589
=	-1.77

Zealand Pharma AS's EBIT per Share for the quarter that ended in Sep. 2024 is calculated as

	EBIT per Share		(Q: Sep. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-38.551	/	70.662
=	-0.55

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.28

Zealand Pharma AS (OTCPK:ZLDPF) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Zealand Pharma AS EBIT per Share Related Terms

Thank you for viewing the detailed overview of Zealand Pharma AS's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Zealand Pharma AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma AS (OTCPK:ZLDPF) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

ZEALc:UK 0NZU:UK ZEAL:Denmark 22Z:Germany

Address

Sydmarken 11, Soborg, DNK, DK-2860

Website

https://www.zealandpharma.com

Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.